Secondary causes of nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease ranging from simple steatosis to nonalcoholic steatohepatitis. The pathophysiology of NAFLD involves increased de novo synthesis of fatty acids in hepatocytes, the retention of lipids due to impaired hepatocyte apolipoprotein secretion or beta-oxidation. The well-known primary causes of NAFLD are obesity, type II diabetes, dyslipidemia, and insulin resistance. However, other less common conditions can cause a similar clinical and histologic picture, and should be considered in patients who present with NAFLD but do not have traditional risk factors. In this review, we discuss uncommon but important causes of NAFLD, including inborn errors of metabolism, iatrogenic causes, viral hepatitis, and nutritional disorders to provide practicing clinicians with an understanding of the less well recognized causes of NAFLD.

[1]  R. Brook,et al.  Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. , 2010, The American journal of medicine.

[2]  G. Langman,et al.  Role of non‐alcoholic steatohepatitis in methotrexate‐induced liver injury , 2001, Journal of gastroenterology and hepatology.

[3]  T. Forrester,et al.  Relation between liver fat content and the rate of VLDL apolipoprotein B-100 synthesis in children with protein-energy malnutrition. , 2005, The American journal of clinical nutrition.

[4]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[5]  J. Allard Other disease associations with non-alcoholic fatty liver disease (NAFLD). , 2002, Best practice & research. Clinical gastroenterology.

[6]  B. Burwinkel,et al.  Severe Phenotype of Phosphorylase Kinase-Deficient Liver Glycogenosis with Mutations in the PHKG2 Gene , 2003, Pediatric Research.

[7]  T. Saphner,et al.  The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer , 2009, Cancer.

[8]  S. Lutsenko,et al.  Systems biology approach to Wilson’s disease , 2011, BioMetals.

[9]  B. Neuschwander‐Tetri Nonalcoholic steatohepatitis and the metabolic syndrome. , 2005, The American journal of the medical sciences.

[10]  N. Crum‐Cianflone,et al.  Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons , 2009, Journal of acquired immune deficiency syndromes.

[11]  M. Rao,et al.  Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. , 2009, Gene expression.

[12]  G. Watts,et al.  Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. , 2008, Clinical science.

[13]  F. Farinati,et al.  Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. , 2003, The Journal of laboratory and clinical medicine.

[14]  W. Chung,et al.  Glycogen Storage Disease Type III diagnosis and management guidelines , 2010, Genetics in Medicine.

[15]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[16]  J. Lewis,et al.  Drug-induced liver disease. , 1989, The Medical clinics of North America.

[17]  R. Coleman,et al.  Neutral lipid storage disease: a genetic disorder with abnormalities in the regulation of phospholipid metabolism. , 1998, Journal of lipid research.

[18]  A. Tanaka [Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[19]  A. Granato,et al.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a , 2002, The Lancet.

[20]  C. Thio,et al.  Liver disease in the HIV-infected individual. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  D. Dhumeaux,et al.  Amiodarone‐induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease , 1988, Hepatology.

[22]  E. Dickson,et al.  Diagnosis of Wilson's disease presenting as fulminant hepatic failure. , 1983, Gastroenterology.

[23]  S. Thung,et al.  Hepatic Weber-Christian disease. , 2001, Seminars in liver disease.

[24]  M. Rinella,et al.  Non-alcoholic fatty liver disease: is bariatric surgery the answer? , 2009, Clinics in liver disease.

[25]  G. Assmann,et al.  Prevalence of cholesteryl ester storage disease. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Swain,et al.  Liver abnormalities in celiac disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  D. Rader,et al.  Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. , 2010, The Journal of clinical investigation.

[28]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[29]  Y. Maehara,et al.  Recurrent familial hypobetalipoproteinemia–induced nonalcoholic fatty liver disease after living donor liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  Andrew J. Brown Viral hepatitis and fatty liver disease: how an unwelcome guest makes pâté of the host. , 2008, The Biochemical journal.

[31]  U. Veronesi,et al.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial , 2005, BMJ : British Medical Journal.

[32]  C. V. D. van der Kallen,et al.  Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. , 2004, The American journal of medicine.

[33]  J. Ludvigsson,et al.  Celiac disease and risk of liver disease: a general population-based study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  B. Clary,et al.  Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. , 2007, Journal of hepatology.

[35]  P. Angulo GI Epidemiology: nonalcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[36]  C. Day Non-alcoholic fatty liver disease: a massive problem. , 2011, Clinical medicine.

[37]  A. Herneth,et al.  Wilson's disease in patients presenting with liver disease: a diagnostic challenge. , 1997, Gastroenterology.

[38]  Satoshi Hirayama,et al.  [Familial hypobetalipoproteinemia]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.